Colistin revisited;Réévaluation de la colistine

Antibiotiques

Volumn 12, Issue 4, 2010, Pages 205-227

  Kipnis, E ^a   Guery, B P ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

A. baumanii; Colistin; P. aeruginosa; Pharmacodynamics; Pharmacokinetics; Resistance

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BACTERIAL PROTEIN; CARBAPENEM DERIVATIVE; COLISTIMETHATE; COLISTIN; MEMBRANE PHOSPHOLIPID; MEMBRANE PROTEIN; RIFAMPICIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; COMBINATION CHEMOTHERAPY; CYSTIC FIBROSIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG POTENTIATION; HOSPITAL INFECTION; HUMAN; IN VIVO STUDY; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR INTERACTION; NEPHROTOXICITY; PROTEIN MODIFICATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

EID: 78650309916     PISSN: 12945501     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antib.2010.10.003     Document Type: Article

References (136)

1. Benedict R.G., Langlykke A.F. Antibiotic activity of bacillus polymyxa. J Bacteriol 1947, 54:24.
2. Bergen P.J., Li J., Rayner C.R., Nation R.L. Colistin methanesulfonate is an inactive prodrug of colistin against pseudomonas aeruginosa. Antimicrob Agents Chemother 2006, 50:1953-1958.
3. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother 2003, 47:1364-1370.
4. Li J., Milne R.W., Nation R.L., Turnidge J.D., Smeaton T.C., Coulthard K. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 2003, 47:1766-1770.
5. Lopes J., Inniss W.E. Electron microscopy of effect of polymyxin on escherichia coli lipopolysaccharide. J Bacteriol 1969, 100:1128-1129.
6. Koike M., Iida K., Matsuo T. Electron microscopic studies on mode of action of polymyxin. J Bacteriol 1969, 97:448-452.
7. Dixon R.A., Chopra I. Polymyxin B and polymyxin B nonapeptide alter cytoplasmic membrane permeability in Escherichia coli. J Antimicrob Chemother 1986, 18:557-563.
8. Dixon R.A., Chopra I. Leakage of periplasmic proteins from Escherichia coli mediated by polymyxin B nonapeptide. Antimicrob Agents Chemother 1986, 29:781-788.
9. Soon R.L., Nation R.L., Hartley P.G., Larson I., Li J. Atomic force microscopy investigation of the morphology and topography of colistin-heteroresistant acinetobacter baumannii strains as a function of growth phase and in response to colistin treatment. Antimicrob Agents Chemother 2009, 53:4979-4986.
10. Littlewood J.M., Koch C., Lambert P.A., Hoiby N., Elborn J.S., Conway S.P., et al. A 10-year review of colomycin. Respir Med 2000, 94:632-640.
11. Pristovsek P., Kidric J. Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: an NMR and molecular modeling study. J Med Chem 1999, 42:4604-4613.
12. Rogers M.J., Cohen J. Comparison of the binding of gram-negative bacterial endotoxin by polymyxin B sulphate, colistin sulphate and colistin sulphomethate sodium. Infection 1986, 14:79-81.
13. Warren H.S., Kania S.A., Siber G.R. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob Agents Chemother 1985, 28:107-112.
14. Gough M., Hancock R.E., Kelly N.M. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996, 64:4922-4927.
15. Stokes D.C., Shenep J.L., Fishman M., Hildner W.K., Bysani G.K., Rufus K. Polymyxin B prevents lipopolysaccharide-induced release of tumor necrosis factor-alpha from alveolar macrophages. J Infect Dis 1989, 160:52-57.
16. Cavaillon J.M., Haeffner-Cavaillon N. Polymyxin-B inhibition of LPS-induced interleukin-1 secretion by human monocytes is dependent upon the LPS origin. Mol Immunol 1986, 23:965-969.
17. Dubor F., Dosne A.M., Chedid L.A. Effect of polymyxin B and colimycin on induction of plasminogen antiactivator by lipopolysaccharide in human endothelial cell culture. Infect Immun 1986, 52:725-729.
18. Catchpole C.R., Andrews J.M., Brenwald N., Wise R. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother 1997, 39:255-260.
19. Li J., Milne R.W., Nation R.L., Turnidge J.D., Smeaton T.C., Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004, 53:837-840.
20. Le Brun P.P., de Graaf A.I., Vinks A.A. High-performance liquid chromatographic method for the determination of colistin in serum. Ther Drug Monit 2000, 22:589-593.
21. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K., Valentine J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 2002, 46:3304-3307.
22. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K., Johnson D.W. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001, 761:167-175.
23. Li J., Rayner C.R., Nation R.L., Deans R., Boots R., Widdecombe N., et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005, 49:4814-4815.
24. Li J. Difficulty in assaying colistin methanesulphonate. Clin Microbiol Infect 2005, 11:773-774.
25. Li J., Coulthard K., Milne R., Nation R.L., Conway S., Peckham D., et al. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J Antimicrob Chemother 2003, 52:987-992.
26. Dudhani R.V., Nation R.L., Li J. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J Antimicrob Chemother 2010, 65:1412-1415.
27. Wallace S.J., Li J., Nation R.L., Prankerd R.J., Velkov T., Boyd B.J. Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization. J Phys Chem B 2010, 114:4836-4840.
28. Plachouras D., Karvanen M., Friberg L.E., Papadomichelakis E., Antoniadou A., Tsangaris I., et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009, 53:3430-3436.
29. Reed M.D., Stern R.C., O'Riordan M.A., Blumer J.L. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol 2001, 41:645-654.
30. Markou N., Markantonis S.L., Dimitrakis E., Panidis D., Boutzouka E., Karatzas S., et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008, 30:143-151.
31. Ratjen F., Rietschel E., Kasel D., Schwiertz R., Starke K., Beier H., et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006, 57:306-311.
32. Jimenez-Mejias M.E., Becerril B., Marquez-Rivas F.J., Pichardo C., Cuberos L., Pachon J. Successful treatment of multidrug-resistant acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium. Eur J Clin Microbiol Infect Dis 2000, 19:970-971.
33. Jimenez-Mejias M.E., Pichardo-Guerrero C., Marquez-Rivas F.J., Martin-Lozano D., Prados T., Pachon J. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis 2002, 21:212-214.
34. Markantonis S.L., Markou N., Fousteri M., Sakellaridis N., Karatzas S., Alamanos I., et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 2009, 53:4907-4910.
35. Falagas M.E., Bliziotis I.A., Tam V.H. Intraventricular or intrathecal use of polymyxins in patients with gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents 2007, 29:9-25.
36. Li J., Turnidge J., Milne R., Nation R.L., Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001, 45:781-785.
37. Owen R.J., Li J., Nation R.L., Spelman D. In vitro pharmacodynamics of colistin against acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007, 59:473-477.
38. Dudhani R.V., Turnidge J.D., Nation R.L., Li J. Fauc/mic is the most predictive pharmacokinetic/pharmacodynamic index of colistin against acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 2010, 65:1412-1415.
39. Dudhani R.V., Turnidge J.D., Coulthard K., Milne R.W., Rayner C.R., Li J., et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010, 54:1117-1124.
40. Michalopoulos A., Kasiakou S.K., Rosmarakis E.S., Falagas M.E. Cure of multidrug-resistant acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis 2005, 37:142-145.
41. Lodise T.P., Lomaestro B., Drusano G.L. Piperacillin-tazobactam for pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007, 44:357-363.
42. Desai T.R., Tyrrell G.J., Ng T., Finlay W.H. In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate. Pharm Res 2003, 20:442-447.
43. Katz S.L., Ho S.L., Coates A.L. Nebulizer choice for inhaled colistin treatment in cystic fibrosis. Chest 2001, 119:250-255.
44. Weber A., Morlin G., Cohen M., Williams-Warren J., Ramsey B., Smith A. Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol 1997, 23:249-260.
45. Kamin W., Schwabe A., Kramer I. Inhalation solutions: which one are allowed to be mixed? Physicochemical compatibility of drug solutions in nebulizers. J Cyst Fibros 2006, 5:205-213.
46. Kasiakou S.K., Rafailidis P.I., Liaropoulos K., Falagas M.E. Cure of post-traumatic recurrent multiresistant gram-negative rod meningitis with intraventricular colistin. J Infect 2005, 50:348-352.
47. Galani I., Kontopidou F., Souli M., Rekatsina P.D., Koratzanis E., Deliolanis J., et al. Colistin susceptibility testing by etest and disk diffusion methods. Int J Antimicrob Agents 2008, 31:434-439.
48. Gales A.C., Reis A.O., Jones R.N. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001, 39:183-190.
49. van der Heijden I.M., Levin A.S., De Pedri E.H., Fung L., Rossi F., Duboc G., et al. Comparison of disc diffusion, etest and broth microdilution for testing susceptibility of carbapenem-resistant P. Aeruginosa to polymyxins. Ann Clin Microbiol Antimicrob 2007, 6:8.
50. Goldstein F.W., Ly A., Kitzis M.D. Comparison of etest with agar dilution for testing the susceptibility of pseudomonas aeruginosa and other multidrug-resistant bacteria to colistin. J Antimicrob Chemother 2007, 59:1039-1040.
51. Tan T.Y., Ng S.Y. Comparison of etest, vitek and agar dilution for susceptibility testing of colistin. Clin Microbiol Infect 2007, 13:541-544.
52. Lo-Ten-Foe J.R., de Smet A.M., Diederen B.M., Kluytmans J.A., van Keulen P.H. Comparative evaluation of the vitek 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant enterobacter cloacae and acinetobacter baumannii strains. Antimicrob Agents Chemother 2007, 51:3726-3730.
53. Tan T.Y., Ng L.S., Poh K. Susceptibility testing of unconventional antibiotics against multiresistant acinetobacter spp. By agar dilution and vitek 2. Diagn Microbiol Infect Dis 2007, 58:357-361.
54. Fernandez-Reyes M., Rodriguez-Falcon M., Chiva C., Pachon J., Andreu D., Rivas L. The cost of resistance to colistin in acinetobacter baumannii: a proteomic perspective. Proteomics 2009, 9:1632-1645.
55. Groisman E.A., Kayser J., Soncini F.C. Regulation of polymyxin resistance and adaptation to low-mg2+ environments. J Bacteriol 1997, 179:7040-7045.
56. Moore R.A., Hancock R.E. Involvement of outer membrane of pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother 1986, 30:923-926.
57. Gunn J.S., Lim K.B., Krueger J., Kim K., Guo L., Hackett M., et al. PMRA-PMRB-regulated genes necessary for 4-aminoarabinose lipid a modification and polymyxin resistance. Mol Microbiol 1998, 27:1171-1182.
58. Fernandez L, Gooderham WJ, Bains M, McPhee JB, Wiegand I, Hancock RE. Adaptive resistance to the " Last hope" antibiotics polymyxin B and colistin in pseudomonas aeruginosa is mediated by the novel two-component regulatory system parr-pars. Antimicrob Agents Chemother;54:3372-82.
59. Sidorczyk Z., Zahringer U., Rietschel E.T. Chemical structure of the lipid a component of the lipopolysaccharide from a proteus mirabilis re-mutant. Eur J Biochem 1983, 137:15-22.
60. Cox A.D., Wilkinson S.G. Ionizing groups in lipopolysaccharides of pseudomonas cepacia in relation to antibiotic resistance. Mol Microbiol 1991, 5:641-646.
61. Hase S., Reitschel E.T. The chemical structure of the lipid a component of lipopolysaccharides from chromobacterium violaceum NCTC 9694. Eur J Biochem 1977, 75:23-34.
62. Nummila K., Kilpelainen I., Zahringer U., Vaara M., Helander I.M. Lipopolysaccharides of polymyxin B-resistant mutants of Escherichia coli are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid A. Mol Microbiol 1995, 16:271-278.
63. 3. Eur J Biochem 1996, 237:272-278.
64. Gilleland H.E., Champlin F.R., Conrad R.S. Chemical alterations in cell envelopes of pseudomonas aeruginosa upon exposure to polymyxin: a possible mechanism to explain adaptive resistance to polymyxin. Can J Microbiol 1984, 30:869-873.
65. Gilleland H.E., Farley L.B. Adaptive resistance to polymyxin in pseudomonas aeruginosa due to an outer membrane impermeability mechanism. Can J Microbiol 1982, 28:830-840.
66. Nicas T.I., Hancock R.E. Outer membrane protein H1 of pseudomonas aeruginosa: involvement in adaptive and mutational resistance to ethylenediaminetetraacetate, polymyxin B, and gentamicin. J Bacteriol 1980, 143:872-878.
67. Bengoechea J.A., Skurnik M. Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in yersinia. Mol Microbiol 2000, 37:67-80.
68. Ito-Kagawa M., Koyama Y. Selective cleavage of a peptide antibiotic, colistin by colistinase. J Antibiot (Tokyo) 1980, 33:1551-1555.
69. Bergen P.J., Li J., Nation R.L., Turnidge J.D., Coulthard K., Milne R.W. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 2008, 61:636-642.
70. Yau W., Owen R.J., Poudyal A., Bell J.M., Turnidge J.D., Yu H.H., et al. Colistin hetero-resistance in multidrug-resistant acinetobacter baumannii clinical isolates from the western pacific region in the sentry antimicrobial surveillance programme. J Infect 2009, 58:138-144.
71. Matthaiou D.K., Michalopoulos A., Rafailidis P.I., Karageorgopoulos D.E., Papaioannou V., Ntani G., et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med 2008, 36:807-811.
72. Mentzelopoulos S.D., Pratikaki M., Platsouka E., Kraniotaki H., Zervakis D., Koutsoukou A., et al. Prolonged use of carbapenems and colistin predisposes to ventilator-associated pneumonia by pandrug-resistant pseudomonas aeruginosa. Intensive Care Med 2007, 33:1524-1532.
73. Antoniadou A., Kontopidou F., Poulakou G., Koratzanis E., Galani I., Papadomichelakis E., et al. Colistin-resistant isolates of klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007, 59:786-790.
74. Cai Y., Li R., Liang B., Bai N., Liu Y., Wang R. In vitro antimicrobial activity and mutant prevention concentration of colistin against acinetobacter baumannii. Antimicrob Agents Chemother 2010, 54:3998-3999.
75. Hogg G.M., Barr J.G., Webb C.H. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of acinetobacter baumannii. J Antimicrob Chemother 1998, 41:494-495.
76. Timurkaynak F., Can F., Azap O.K., Demirbilek M., Arslan H., Karaman S.O. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of pseudomonas aeruginosa and acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006, 27:224-228.
77. Li J., Nation R.L., Owen R.J., Wong S., Spelman D., Franklin C. Antibiograms of multidrug-resistant clinical acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 2007, 45:594-598.
78. Giamarellos-Bourboulis E.J., Xirouchaki E., Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant acinetobacter baumannii. Diagn Microbiol Infect Dis 2001, 40:117-120.
79. Song J.Y., Kee S.Y., Hwang I.S., Seo Y.B., Jeong H.W., Kim W.J., et al. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant acinetobacter baumannii. J Antimicrob Chemother 2007, 60:317-322.
80. Tascini C., Gemignani G., Ferranti S., Tagliaferri E., Leonildi A., Lucarini A., et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant pseudomonas aeruginosa infections. J Chemother (Florence, Italy) 2004, 16:282-287.
81. Giamarellos-Bourboulis E.J., Sambatakou H., Galani I., Giamarellou H. In vitro interaction of colistin and rifampin on multidrug-resistant pseudomonas aeruginosa. J Chemother (Florence, Italy) 2003, 15:235-238.
82. Giamarellos-Bourboulis E.J., Karnesis L., Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2002, 44:259-263.
83. Tan T.Y., Ng L.S., Tan E., Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant acinetobacter baumannii clinical isolates. J Antimicrob Chemother 2007, 60:421-423.
84. Souli M., Rekatsina P.D., Chryssouli Z., Galani I., Giamarellou H., Kanellakopoulou K. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing klebsiella pneumoniae isolates?. Antimicrob Agents Chemother 2009, 53:2133-2135.
85. Giacometti A., Cirioni O., Ghiselli R., Orlando F., Mocchegiani F., D'Amato G., et al. Antiendotoxin activity of antimicrobial peptides and glycopeptides. J Chemother 2003, 15:129-133.
86. Montero A., Ariza J., Corbella X., Domenech A., Cabellos C., Ayats J., et al. Antibiotic combinations for serious infections caused by carbapenem-resistant acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 2004, 54:1085-1091.
87. Pantopoulou A., Giamarellos-Bourboulis E.J., Raftogannis M., Tsaganos T., Dontas I., Koutoukas P., et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 2007, 29:51-55.
88. Cirioni O., Ghiselli R., Orlando F., Silvestri C., Mocchegiani F., Rocchi M., et al. Efficacy of colistin/rifampin combination in experimental rat models of sepsis due to a multiresistant pseudomonas aeruginosa strain. Crit Care Med 2007, 35:1717-1723.
89. Petrosillo N., Chinello P., Proietti M.F., Cecchini L., Masala M., Franchi C., et al. Combined colistin and rifampicin therapy for carbapenem-resistant acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 2005, 11:682-683.
90. Mendes R.E., Fritsche T.R., Sader H.S., Jones R.N. Increased antimicrobial susceptibility profiles among polymyxin-resistant acinetobacter baumannii clinical isolates. Clin Infect Dis 2008, 46:1324-1326.
91. Hegreness M., Shoresh N., Damian D., Hartl D., Kishony R. Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci U S A 2008, 105:13977-13981.
92. Yeh P.J., Hegreness M.J., Aiden A.P., Kishony R. Drug interactions and the evolution of antibiotic resistance. Nat Rev Microbiol 2009, 7:460-466.
93. Torella J.P., Chait R., Kishony R. Optimal drug synergy in antimicrobial treatments. PLoS Comput Biol 2010, 6:e1000796.
94. Koch-Weser J., Sidel V.W., Federman E.B., Kanarek P., Finer D.C., Eaton A.E. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970, 72:857-868.
95. Bosso J.A., Liptak C.A., Seilheimer D.K., Harrison G.M. Toxicity of colistin in cystic fibrosis patients. DICP Ann Pharmacother 1991, 25:1168-1170.
96. Cheng C.Y., Sheng W.H., Wang J.T., Chen Y.C., Chang S.C. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant gram-negative bacterial infections. Int J Antimicrob Agents 2010, 35:297-300.
97. Wahby K., Chopra T., Chandrasekar P. Intravenous and inhalational colistin-induced respiratory failure. Clin Infect Dis 2010, 50:e38-e40.
98. Lindesmith L.A., Baines R.D., Bigelow D.B., Petty T.L. Reversible respiratory paralysis associated with polymyxin therapy. Ann Int Med 1968, 68:318-327.
99. Evagelopoulou P., Katsaros A., Myrianthefs P., Karatzas S., Boutzouka E., Fildissis G., et al. Colistin and rhabdomyolysis: a causative agent or an innocent bystander?. Intensive Care Med 2007, 33:556-557.
100. Dodd M.E., Abbott J., Maddison J., Moorcroft A.J., Webb A.K. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997, 52:656-658.
101. Maddison J., Dodd M., Webb A.K. Nebulized colistin causes chest tightness in adults with cystic fibrosis. Respir Med 1994, 88:145-147.
102. Alothman G.A., Ho B., Alsaadi M.M., Ho S.L., O'Drowsky L., Louca E., et al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005, 127:522-529.
103. Jasani B., Kreil G., Mackler B.F., Stanworth D.R. Further studies on the structural requirements for polypeptide-mediated histamine release from rat mast cells. Biochem J 1979, 181:623-632.
104. Westerman E.M., Le Brun P.P., Touw D.J., Frijlink H.W., Heijerman H.G. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros 2004, 3:23-28.
105. McCoy K.S. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med 2007, 357:2310-2311.
106. Price D.J., Graham D.I. Effects of large doses of colistin sulphomethate sodium on renal function. Br Med J 1970, 4:525-527.
107. Randall R.E., Bridi G.S., Setter J.G., Brackett N.C. Recovery from colistimethate nephrotoxicity. Ann Intern Med 1970, 73:491-492.
108. Paul M., Bishara J., Levcovich A., Chowers M., Goldberg E., Singer P., et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 2010, 65:1019-1027.
109. Garnacho-Montero J., Ortiz-Leyba C., Jimenez-Jimenez F.J., Barrero-Almodovar A.E., Garcia-Garmendia J.L., Bernabeu-Wittel I.M., et al. Treatment of multidrug-resistant acinetobacter baumannii ventilator-associated pneumonia (vap) with intravenous colistin: a comparison with imipenem-susceptible vap. Clin Infect Dis 2003, 36:1111-1118.
110. Pintado V., San Miguel L.G., Grill F., Mejia B., Cobo J., Fortun J., et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008, 56:185-190.
111. Gounden R., Bamford C., van Zyl-Smit R., Cohen K., Maartens G. Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant acinetobacter baumannii infections. BMC Infect Dis 2009, 9:26.
112. Kasiakou S.K., Michalopoulos A., Soteriades E.S., Samonis G., Sermaides G.J., Falagas M.E. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005, 49:3136-3146.
113. Falagas M.E., Rafailidis P.I., Ioannidou E., Alexiou V.G., Matthaiou D.K., Karageorgopoulos D.E., et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010, 35:194-199.
114. Markou N., Apostolakos H., Koumoudiou C., Athanasiou M., Koutsoukou A., Alamanos I., et al. Intravenous colistin in the treatment of sepsis from multiresistant gram-negative bacilli in critically ill patients. Crit Care 2003, 7:R78-R83.
115. Michalopoulos A.S., Tsiodras S., Rellos K., Mentzelopoulos S., Falagas M.E. Colistin treatment in patients with icu-acquired infections caused by multiresistant gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005, 11:115-121.
116. Levin A.S., Barone A.A., Penco J., Santos M.V., Marinho I.S., Arruda E.A., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant pseudomonas aeruginosa and acinetobacter baumannii. Clin Infect Dis 1999, 28:1008-1011.
117. Hartzell J.D., Neff R., Ake J., Howard R., Olson S., Paolino K., et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009, 48:1724-1728.
118. Falagas M.E., Fragoulis K.N., Kasiakou S.K., Sermaidis G.J., Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005, 26:504-507.
119. Falagas M.E., Rizos M., Bliziotis I.A., Rellos K., Kasiakou S.K., Michalopoulos A. Toxicity after prolonged (more than 4 weeks) administration of intravenous colistin. BMC Infect Dis 2005, 5:1.
120. Lewis J.R., Lewis S.A. Colistin interactions with the mammalian urothelium. Am J Physiol Cell Physiol 2004, 286:C913-C922.
121. Conway S.P., Pond M.N., Watson A., Etherington C., Robey H.L., Goldman M.H. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997, 52:987-993.
122. Linden P.K., Kusne S., Coley K., Fontes P., Kramer D.J., Paterson D. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant pseudomonas aeruginosa. Clin Infect Dis 2003, 37:e154-e160.
123. Reina R., Estenssoro E., Sàenz G., Canales H.S., Gonzalvo R., Vidal G., et al. Safety and efficacy of colistin in acinetobacter and pseudomonas infections: a prospective cohort study. Intensive Care Med 2005, 31:1058-1065.
124. Falagas M.E., Rafailidis P.I., Kasiakou S.K., Hatzopoulou P., Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy versus Colistin-meropenem combination therapy for multidrug-resistant gram-negative bacterial infections. Clin Microbiol Infect 2006, 12:1227-1230.
125. Tascini C., Gemignani G., Palumbo F., Leonildi A., Tedeschi A., Lambelet P., et al. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother 2006, 18:648-651.
126. Trottier V., Namias N., Pust D.G., Nuwayhid Z., Manning R., Marttos A.C., et al. Outcomes of acinetobacter baumannii infection in critically ill surgical patients. Surg Infect (Larchmt) 2007, 8:437-443.
127. Koomanachai P., Tiengrim S., Kiratisin P., Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant pseudomonas aeruginosa and acinetobacter baumannii in Siriraj hospital, Bangkok, Thailand. Int J Infect Dis 2007, 11:402-406.
128. Hachem R.Y., Chemaly R.F., Ahmar C.A., Jiang Y., Boktour M.R., Rjaili G.A., et al. Colistin is effective in treatment of infections caused by multidrug-resistant pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007, 51:1905-1911.
129. Bassetti M., Repetto E., Righi E., Boni S., Diverio M., Molinari M.P., et al. Colistin and rifampicin in the treatment of multidrug-resistant acinetobacter baumannii infections. J Antimicrob Chemother 2008, 61:417-420.
130. Kumar A., Ellis P., Arabi Y., Roberts D., Light B., Parrillo J.E., et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009, 136:1237-1248.
131. Reina R., Estenssoro E., Saenz G., Canales H.S., Gonzalvo R., Vidal G., et al. Safety and efficacy of colistin in acinetobacter and pseudomonas infections: a prospective cohort study. Intensive Care Med 2005, 31:1058-1065.
132. Kallel H., Hergafi L., Bahloul M., Hakim A., Dammak H., Chelly H., et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007, 33:1162-1167.
133. Rios F.G., Luna C.M., Maskin B., Saenz Valiente A., Lloria M., Gando S., et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 2007, 30:307-313.
134. Hoiby N., Frederiksen B., Pressler T. Eradication of early pseudomonas aeruginosa infection. J Cyst Fibros 2005, 4(Suppl. 2):49-54.
135. Liberati A., D'Amico R., Pifferi S., Torri V., Brazzi L., Parmelli E. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev 2009, 4:CD000022.
136. de Smet A.M., Kluytmans J.A., Cooper B.S., Mascini E.M., Benus R.F., van der Werf T.S., et al. Decontamination of the digestive tract and oropharynx in icu patients. N Engl J Med 2009, 360:20-31.